-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFV-890 in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFV-890 in Inflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFV-890 in Inflammation Drug Details: DFV-890 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFV-890 in Familial Cold Autoinflammatory Syndrome (Familial Cold Urticaria)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFV-890 in Familial Cold Autoinflammatory Syndrome (Familial Cold Urticaria) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFV-890 in Familial Cold Autoinflammatory Syndrome...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levosimendan in Subarachnoid Hemorrhage
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levosimendan in Subarachnoid Hemorrhage report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levosimendan in Subarachnoid Hemorrhage Drug Details: Levosimendan (Simdax, Zimino) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tenecteplase in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tenecteplase in Acute Ischemic Stroke report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tenecteplase in Acute Ischemic Stroke Drug Details: Tenecteplase (Metalyse, Tnkase)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tenecteplase in Acute Respiratory Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tenecteplase in Acute Respiratory Failure report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tenecteplase in Acute Respiratory Failure Drug Details: Tenecteplase (Metalyse, Tnkase)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levosimendan in Pulmonary Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levosimendan in Pulmonary Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levosimendan in Pulmonary Hypertension Drug Details: Levosimendan (Simdax, Zimino) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inclisiran in Homozygous Familial Hypercholesterolemia (HoFH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inclisiran in Homozygous Familial Hypercholesterolemia (HoFH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inclisiran in Homozygous Familial Hypercholesterolemia (HoFH) Drug Details: Inclisiran...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inclisiran in Acute Coronary Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inclisiran in Acute Coronary Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inclisiran in Acute Coronary Syndrome Drug Details: Inclisiran (Leqvio, Sybrava)...
-
Sector Analysis
NewIndia General Insurance Market Size and Trends by Line of Business, Distribution, Competitive Landscape and Forecast to 2028
India General Insurance Market Report Overview The gross written premium of the Indian general insurance market was INR3 trillion ($36.5 billion) in 2023. The Indian general insurance sector growth peaked in 2022 and slowed down the following year majorly due to a decrease in liability, crop, credit guarantee, and marine, aviation, and transit (MAT) insurance premiums. The growth is anticipated to slow down over 2024–28 at a CAGR of more than 9%, due to elevated interest rates and medical inflation....